Prometrium Self-Injection Technique: Why It Doesn't Apply (and How to Take Micronized Progesterone Correctly)

Prometrium Is Not an Injectable: Clearing Up the Confusion

Prometrium is an oral capsule. There is no self-injection technique because no injectable formulation of this specific brand exists. The confusion likely stems from the fact that progesterone itself is available in an intramuscular (IM) oil preparation (progesterone in oil, 50 mg/mL) and as a subcutaneous formulation (Subcutaneous Progesterone, marketed outside the U.S.), both used primarily in fertility protocols and luteal phase support. Those are different products with different brand names, concentrations, and indications.

Prometrium's FDA-approved labeling specifies oral administration only [1]. The capsule contains micronized progesterone suspended in peanut oil inside a gelatin shell. Micronization, the process of reducing particle size to 10 microns or less, increases the surface area of the progesterone crystals and improves gastrointestinal absorption, which is why the oral route became viable in the first place. Earlier non-micronized oral progesterone formulations had such poor bioavailability that injectable progesterone was the only reliable systemic option for decades.

If your clinician has prescribed injectable progesterone in oil for IVF or luteal support, that is a separate medication. Do not attempt to extract or inject the contents of a Prometrium capsule.

How to Take Prometrium Orally: Proper Technique

The correct oral administration is straightforward but timing matters. Take the capsule whole with a glass of water at bedtime. The FDA prescribing information specifies bedtime dosing for a reason: micronized progesterone is metabolized in the liver to allopregnanolone, a neurosteroid that binds GABA-A receptors and produces sedation [2]. Taking it at night turns this side effect into a mild sleep aid.

Food increases the bioavailability of oral micronized progesterone. A study published in Fertility and Sterility found that peak serum progesterone concentrations (Cmax) were approximately 6- to 7-fold higher when Prometrium was taken with food compared to fasting [3]. Despite this pharmacokinetic reality, the label recommends taking it at bedtime without specifying food, and most clinicians advise a small snack if the patient eats dinner early. Avoid grapefruit juice, which may inhibit CYP3A4 and alter metabolism.

For cyclical HRT regimens, the standard dose is 200 mg nightly for 12 days of a 28-day cycle. For continuous combined regimens, the dose drops to 100 mg nightly. Swallow the capsule whole. Do not chew, crush, or open it.

Off-Label Vaginal Administration: When and Why Clinicians Prescribe It

Reproductive endocrinologists frequently prescribe Prometrium capsules for vaginal insertion, even though this route is not on the FDA label. The rationale is pharmacokinetic: vaginal administration bypasses first-pass hepatic metabolism, delivers higher local endometrial progesterone concentrations, and produces less drowsiness because less allopregnanolone reaches the central nervous system [4].

A randomized trial by Miles et al. (1994) demonstrated that vaginal micronized progesterone produced endometrial secretory transformation comparable to intramuscular progesterone, with serum levels that were lower but endometrial tissue concentrations that were adequate. This "uterine first-pass effect" explains why vaginal progesterone works for luteal support in IVF despite producing lower blood levels than IM injections [4].

For vaginal insertion of a Prometrium capsule, the technique is simple: wash hands, insert the capsule high into the vaginal canal (similar to a suppository), and remain recumbent for 15 to 20 minutes to reduce leakage. Some patients experience a waxy residue from the dissolved capsule shell. This is expected. The off-label vaginal route is commonly dosed at 100 to 200 mg once or twice daily, depending on the clinical scenario. Always follow your prescriber's specific instructions.

How Does Prometrium Work? Mechanism of Action

Micronized progesterone is bioidentical to the progesterone produced by the corpus luteum. It is not a synthetic progestin. That distinction carries real clinical weight.

After oral absorption and first-pass metabolism, progesterone binds to the nuclear progesterone receptor (PR), which exists in two isoforms: PR-A and PR-B [5]. When progesterone binds these receptors in endometrial cells, it opposes estrogen-driven proliferation by downregulating estrogen receptors, activating enzymes that convert estradiol to less potent estrone sulfate, and shifting the endometrium from a proliferative to a secretory state. This is the core reason progesterone is prescribed alongside estrogen in HRT for women with an intact uterus: unopposed estrogen stimulation raises the risk of endometrial hyperplasia and carcinoma [6].

Beyond the endometrium, progesterone acts on multiple tissue targets. In the brain, its metabolite allopregnanolone modulates GABA-A receptor activity, which accounts for the anxiolytic and sedative properties. In breast tissue, micronized progesterone appears to have a more favorable safety profile than synthetic progestins like medroxyprogesterone acetate (MPA). The E3N French cohort study (N=80,377) found that estrogen combined with micronized progesterone was not associated with an increased risk of breast cancer over a mean follow-up of 8.1 years, while estrogen plus synthetic progestins carried a significantly elevated risk (RR 1.69; 95% CI 1.50 to 1.91) [7].

Progesterone also binds mineralocorticoid receptors as an antagonist, which may produce a mild antimineralocorticoid (anti-bloating) effect, and it has thermogenic properties, raising basal body temperature by approximately 0.3 to 0.5°C during the luteal phase.

The PEPI Trial: Landmark Evidence for Micronized Progesterone

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial remains the most cited study supporting Prometrium's place in HRT. Published in JAMA in 1995, PEPI was a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 875 healthy postmenopausal women and followed them for 3 years [6].

PEPI compared five arms: placebo, conjugated equine estrogens (CEE) alone, CEE plus MPA (cyclical), CEE plus MPA (continuous), and CEE plus micronized progesterone (cyclical, 200 mg/day for 12 days per cycle). The primary endpoints were cardiovascular risk factors: HDL cholesterol, LDL cholesterol, fibrinogen, insulin, and blood pressure.

The results showed three things clearly. First, all active estrogen-containing regimens improved HDL, LDL, and fibrinogen compared to placebo. Second, CEE alone produced the greatest HDL increase (+5.6 mg/dL) but caused endometrial hyperplasia in 33.6% of participants by year 3, making it unacceptable as monotherapy in women with a uterus. Third, micronized progesterone preserved more of estrogen's HDL benefit (+4.1 mg/dL) than either MPA regimen (cyclical MPA: +1.6 mg/dL; continuous MPA: +1.2 mg/dL), while still providing full endometrial protection with a hyperplasia rate of only 0.8% [6].

The PEPI finding drove a shift in clinical practice. The Endocrine Society and the North American Menopause Society (NAMS) now recognize micronized progesterone as a preferred progestogen option in HRT, particularly for women concerned about cardiovascular and breast cancer risk profiles [8][9].

Micronized Progesterone vs. Synthetic Progestins: Why the Difference Matters

Not all progestogens are the same molecule, and they do not carry the same risks. MPA, the progestin used in the Women's Health Initiative (WHI), binds the glucocorticoid receptor and the androgen receptor in addition to the progesterone receptor. Micronized progesterone does not have significant androgenic or glucocorticoid activity.

This pharmacologic distinction maps to clinical outcomes. The WHI (N=16,608) found that CEE plus MPA increased breast cancer risk (HR 1.26; 95% CI 1.00 to 1.59) and coronary events in the first year of use [10]. The E3N cohort, by contrast, found no increased breast cancer risk with estrogen plus micronized progesterone over 8 years of follow-up [7]. While these are different study designs (RCT vs. observational), the E3N data were large enough and the follow-up long enough that the 2022 NAMS position statement noted micronized progesterone's potentially more favorable breast safety profile compared to MPA [9].

On the cardiovascular side, MPA blunted estrogen's HDL benefit in PEPI by approximately 75%. Micronized progesterone blunted it by only 27% [6]. For patients and clinicians weighing progestogen options, these numbers matter.

The tradeoff: micronized progesterone has a shorter half-life (approximately 16 to 18 hours for the oral route) and must be taken daily for adequate endometrial suppression. MPA's longer duration of action allows more flexible dosing in some regimens.

Dosing Protocols: Cyclical vs. Continuous Regimens

Two main dosing strategies exist for micronized progesterone in HRT, and the choice depends on where a patient is in the menopausal transition.

Cyclical (sequential) dosing is typically used in perimenopausal women or those within the first one to two years of menopause. The protocol is 200 mg at bedtime for 12 to 14 days of each calendar month, paired with continuous daily estrogen. This produces a predictable withdrawal bleed, which many patients in early menopause find reassuring because it mimics a natural cycle. The PEPI trial used this 12-day cyclical schedule and confirmed adequate endometrial protection [6].

Continuous combined dosing is preferred for women who are at least 12 months past their final menstrual period and who want to avoid monthly bleeding. The dose is 100 mg nightly, taken every day alongside daily estrogen. Breakthrough spotting is common in the first 3 to 6 months but typically resolves. A Cochrane review of continuous combined HRT regimens found that endometrial safety was maintained with daily micronized progesterone at 100 mg, though some data suggest that 200 mg continuous may be needed in women with higher BMI or higher endogenous estrone conversion [11].

Prescribers occasionally use a "long-cycle" protocol: 200 mg for 14 days every 3 months. This approach reduces progestogen exposure but carries a slightly higher risk of endometrial stimulation between progesterone phases. It requires more frequent endometrial monitoring, typically via transvaginal ultrasound, and is not a first-line approach per ACOG guidelines [12].

Side Effects and Safety Considerations

The most common side effect of oral Prometrium is drowsiness, reported in approximately 24% of patients in clinical trials [1]. This is dose-dependent and directly related to allopregnanolone. Vaginal administration largely eliminates this effect.

Other reported side effects include bloating, breast tenderness, headache, and mood changes. These overlap substantially with symptoms of endogenous progesterone in the luteal phase, which is expected given the bioidentical nature of the molecule.

The peanut oil excipient is a genuine safety concern for patients with peanut allergies. The FDA label carries a warning about this, and alternative progesterone formulations (compounded micronized progesterone in a non-peanut oil base, or vaginal progesterone gels like Crinone) should be used in these patients [1].

Contraindications include known or suspected breast cancer, active arterial thromboembolic disease (stroke, MI), known hypersensitivity to progesterone or peanuts, hepatic dysfunction, and undiagnosed vaginal bleeding. Prometrium should not be used as a contraceptive; it does not reliably suppress ovulation at standard HRT doses.

When Injectable Progesterone Is Actually Indicated

For patients who did arrive at this page looking for injection guidance, injectable progesterone in oil (not Prometrium) is a real medication used in specific scenarios. IM progesterone in oil at 50 mg daily is a standard luteal-phase support protocol in IVF cycles [13]. The injection is given in the upper outer quadrant of the gluteal muscle using an 18-gauge needle to draw and a 22-gauge 1.5-inch needle to inject. The oil should be warmed to body temperature before injection to reduce viscosity and injection-site pain.

A 2018 Cochrane review found that vaginal progesterone and IM progesterone produced comparable live birth rates in IVF luteal support (RR 1.01; 95% CI 0.93 to 1.10), leading many reproductive endocrinologists to favor the vaginal route for patient comfort [14]. If you have been prescribed injectable progesterone for fertility treatment, ask your clinic for a specific injection demonstration. Technique matters: injection-site abscesses and oil embolism (rare but serious) are avoidable with proper training.